{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:18:36Z","timestamp":1790716716041,"version":"4.1.0"},"reference-count":136,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2018.00054","type":"journal-article","created":{"date-parts":[[2018,3,7]],"date-time":"2018-03-07T04:40:55Z","timestamp":1520397655000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":72,"title":["Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells"],"prefix":"10.3389","volume":"8","author":[{"given":"Thomas","family":"Menter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,3,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1053\/j.seminoncol.2015.05.013","article-title":"Antagonists of PD-1 and PD-L1 in cancer treatment","volume":"42","author":"Lipson","year":"2015","journal-title":"Semin Oncol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1200\/JCO.2012.46.6193","article-title":"Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors","volume":"31","author":"Hahn","year":"2013","journal-title":"J Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1053\/j.seminoncol.2015.05.003","article-title":"Cancer and the immune system: basic concepts and targets for intervention","volume":"42","author":"Pardoll","year":"2015","journal-title":"Semin Oncol"},{"key":"B4","first-page":"43","article-title":"The nude mouse vs. the hypothesis of immunological surveillance","volume":"28","author":"Rygaard","year":"1976","journal-title":"Transplant Rev"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1038\/35074122","article-title":"IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity","volume":"410","author":"Shankaran","year":"2001","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1038\/nri1961","article-title":"Interferons, immunity and cancer immunoediting","volume":"6","author":"Dunn","year":"2006","journal-title":"Nat Rev Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1093\/carcin\/bgs124","article-title":"Immune surveillance of senescent cells \u2013 biological significance in cancer- and non-cancer pathologies","volume":"33","author":"Hoenicke","year":"2012","journal-title":"Carcinogenesis"},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1111\/joim.12470","article-title":"The immune system and cancer evasion strategies: therapeutic concepts","volume":"279","author":"Muenst","year":"2016","journal-title":"J Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"755","DOI":"10.2174\/1568009615666151030102250","article-title":"Indoleamine 2,3-dioxygenase (IDO): biology and target in cancer immunotherapies","volume":"16","author":"Selvan","year":"2016","journal-title":"Curr Cancer Drug Targets"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e154.1","DOI":"10.1038\/cti.2017.43","article-title":"Regulatory T-cell heterogeneity and the cancer immune response","volume":"6","author":"Ward-Hartstonge","year":"2017","journal-title":"Clin Transl Immunology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/vaccines4030028","article-title":"Regulatory T cells in the tumor microenvironment and cancer progression: role and therapeutic targeting","volume":"4","author":"Chaudhary","year":"2016","journal-title":"Vaccines (Basel)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"6795","DOI":"10.1158\/0008-5472.CAN-17-2285","article-title":"Discovery of IDO1 inhibitors: from bench to bedside","volume":"77","author":"Prendergast","year":"2017","journal-title":"Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s00262-014-1549-4","article-title":"Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer","volume":"63","author":"Prendergast","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"72322","DOI":"10.18632\/oncotarget.11875","article-title":"Addressing intra-tumoral heterogeneity and therapy resistance","volume":"7","author":"Rybinski","year":"2016","journal-title":"Oncotarget"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1016\/j.molonc.2015.10.009","article-title":"Cancer immunotherapy: strategies for personalization and combinatorial approaches","volume":"9","author":"Sathyanarayanan","year":"2015","journal-title":"Mol Oncol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1968","DOI":"10.1056\/NEJMe078173","article-title":"Hodgkin\u2019s disease \u2013 from pathology specimen to cure","volume":"357","author":"Diehl","year":"2007","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Kuppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B21","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1053\/j.seminhematol.2016.05.007","article-title":"Hodgkin lymphoma: pathology and biology","volume":"53","author":"Mathas","year":"2016","journal-title":"Semin Hematol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.humpath.2016.03.005","article-title":"Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas","volume":"54","author":"Menter","year":"2016","journal-title":"Hum Pathol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.ccr.2010.11.013","article-title":"Cooperative epigenetic modulation by cancer amplicon genes","volume":"18","author":"Rui","year":"2010","journal-title":"Cancer Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"B33","doi-asserted-by":"publisher","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin\u2019s lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2326-6066.CIR-16-0201","article-title":"Classical Hodgkin lymphoma with reduced beta2M\/MHC class I expression is associated with inferior outcome independent of 9p24.1 status","volume":"4","author":"Roemer","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1365-2249.1992.tb05842.x","article-title":"Hodgkin\u2019s cells express a novel pattern of adhesion molecules","volume":"90","author":"Ellis","year":"1992","journal-title":"Clin Exp Immunol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1002\/gcc.22276","article-title":"Alterations of the CD58 gene in classical Hodgkin lymphoma","volume":"54","author":"Schneider","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/gene.2016.30","article-title":"CD58 mutations are common in Hodgkin lymphoma cell lines and loss of CD58 expression in tumor cells occurs in Hodgkin lymphoma patients who relapse","volume":"17","author":"Abdul Razak","year":"2016","journal-title":"Genes Immun"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2606.1","DOI":"10.4081\/ejh.2016.2606","article-title":"HLA-G expression and role in advanced-stage classical Hodgkin lymphoma","volume":"60","author":"Caocci","year":"2016","journal-title":"Eur J Histochem"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1136\/jcp.2007.050146","article-title":"Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma","volume":"60","author":"Kapatai","year":"2007","journal-title":"J Clin Pathol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"4339","DOI":"10.1182\/blood-2005-06-2341","article-title":"Rescue of \u201ccrippled\u201dgerminal center B cells from apoptosis by Epstein-Barr virus","volume":"106","author":"Mancao","year":"2005","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1002\/ijc.22511","article-title":"The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin\u2019s lymphoma","volume":"120","author":"Renne","year":"2007","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/asheducation-2012.1.328","article-title":"New insights in the biology of Hodgkin lymphoma","volume":"2012","author":"Kuppers","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.1182\/blood-2017-06-781989","article-title":"Signaling pathways and immune evasion mechanisms in classical Hodgkin lymphoma","volume":"130","author":"Liu","year":"2017","journal-title":"Blood"},{"key":"B46","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1038\/70932","article-title":"B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion","volume":"5","author":"Dong","year":"1999","journal-title":"Nat Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1016\/j.molimm.2011.06.436","article-title":"PD-L2 is expressed on activated human T cells and regulates their function","volume":"48","author":"Messal","year":"2011","journal-title":"Mol Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S1074-7613(04)00051-2","article-title":"Structural and functional analysis of the costimulatory receptor programmed death-1","volume":"20","author":"Zhang","year":"2004","journal-title":"Immunity"},{"key":"B50","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","volume":"206","author":"Francisco","year":"2009","journal-title":"J Exp Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"159.1","DOI":"10.1186\/s12916-016-0711-6","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma","volume":"14","author":"Guo","year":"2016","journal-title":"BMC Med"},{"key":"B53","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/1074-7613(95)90125-6","article-title":"Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4","volume":"3","author":"Tivol","year":"1995","journal-title":"Immunity"},{"key":"B54","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1126\/science.291.5502.319","article-title":"Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice","volume":"291","author":"Nishimura","year":"2001","journal-title":"Science"},{"key":"B55","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1517\/14728222.2014.980235","article-title":"The PD-1\/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy","volume":"19","author":"Muenst","year":"2015","journal-title":"Expert Opin Ther Targets"},{"key":"B56","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.febslet.2004.07.083","article-title":"PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70\/CD3zeta signalosome and downstream signaling to PKCtheta","volume":"574","author":"Sheppard","year":"2004","journal-title":"FEBS Lett"},{"key":"B57","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/emmm.201100165","article-title":"PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells","volume":"3","author":"Karwacz","year":"2011","journal-title":"EMBO Mol Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"385.1","DOI":"10.21037\/atm.2017.06.11","article-title":"Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy","volume":"5","author":"Zuazo","year":"2017","journal-title":"Ann Transl Med"},{"key":"B59","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1182\/blood-2015-02-629600","article-title":"Expression of programmed cell death ligand 1 is associated with poor overall survival in patients with diffuse large B-cell lymphoma","volume":"126","author":"Kiyasu","year":"2015","journal-title":"Blood"},{"key":"B60","doi-asserted-by":"publisher","first-page":"953","DOI":"10.3324\/haematol.2012.077537","article-title":"The PD-1\/PD-L1 axis contributes to T-cell dysfunction in chronic lymphocytic leukemia","volume":"98","author":"Brusa","year":"2013","journal-title":"Haematologica"},{"key":"B61","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s00277-017-3127-2","article-title":"PD1 blockade with low-dose nivolumab in NK\/T cell lymphoma failing L-asparaginase: efficacy and safety","volume":"97","author":"Chan","year":"2017","journal-title":"Ann Hematol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2062","DOI":"10.1182\/blood-2013-10-535443","article-title":"Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma","volume":"123","author":"Twa","year":"2014","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"3026","DOI":"10.1182\/blood-2015-12-686550","article-title":"Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas","volume":"127","author":"Georgiou","year":"2016","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1182\/blood-2015-10-673236","article-title":"Targetable genetic features of primary testicular and primary central nervous system lymphomas","volume":"127","author":"Chapuy","year":"2016","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","first-page":"20852","DOI":"10.1073\/pnas.0810958105","article-title":"Oncogenic kinase NPM\/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1)","volume":"105","author":"Marzec","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B66","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/cas.13194","article-title":"Suppressors of cytokine signaling: potential immune checkpoint molecules for cancer immunotherapy","volume":"108","author":"Chikuma","year":"2017","journal-title":"Cancer Sci"},{"key":"B67","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/nature18294","article-title":"Aberrant PD-L1 expression through 3\u2019-UTR disruption in multiple cancers","volume":"534","author":"Kataoka","year":"2016","journal-title":"Nature"},{"key":"B68","doi-asserted-by":"publisher","first-page":"59976","DOI":"10.18632\/oncotarget.11045","article-title":"PD-L1 expression in EBV-negative diffuse large B-cell lymphoma: clinicopathologic features and prognostic implications","volume":"7","author":"Xing","year":"2016","journal-title":"Oncotarget"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1182\/blood-2017-01-764209","article-title":"PD-1 blockade with nivolumab in relapsed\/refractory primary central nervous system and testicular lymphoma","volume":"129","author":"Nayak","year":"2017","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","first-page":"E436","DOI":"10.1002\/ajh.24485","article-title":"The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome","volume":"91","author":"Bledsoe","year":"2016","journal-title":"Am J Hematol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"e0166266.1","DOI":"10.1371\/journal.pone.0166266","article-title":"PD-L1 status in refractory lymphomas","volume":"11","author":"Vranic","year":"2016","journal-title":"PLoS One"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/328267a0","article-title":"A new member of the immunoglobulin superfamily \u2013 CTLA-4","volume":"328","author":"Brunet","year":"1987","journal-title":"Nature"},{"key":"B74","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1084\/jem.192.2.303","article-title":"Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4","volume":"192","author":"Takahashi","year":"2000","journal-title":"J Exp Med"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.4049\/jimmunol.165.3.1352","article-title":"CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression","volume":"165","author":"Carreno","year":"2000","journal-title":"J Immunol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1038\/35069118","article-title":"Crystal structure of the B7-1\/CTLA-4 complex that inhibits human immune responses","volume":"410","author":"Stamper","year":"2001","journal-title":"Nature"},{"key":"B77","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/(SICI)1521-4141(199903)29:03<838::AID-IMMU838>3.0.CO;2-P","article-title":"CTLA4 ligation attenuates AP-1, NFAT and NF-kappaB activity in activated T cells","volume":"29","author":"Fraser","year":"1999","journal-title":"Eur J Immunol"},{"key":"B78","doi-asserted-by":"crossref","first-page":"5813","DOI":"10.4049\/jimmunol.162.10.5813","article-title":"CTLA-4-mediated inhibition of early events of T cell proliferation","volume":"162","author":"Brunner","year":"1999","journal-title":"J Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1084\/jem.186.10.1645","article-title":"Cytotoxic T lymphocyte antigen 4 (CTLA-4) interferes with extracellular signal-regulated kinase (ERK) and Jun NH2-terminal kinase (JNK) activation, but does not affect phosphorylation of T cell receptor zeta and ZAP70","volume":"186","author":"Calvo","year":"1997","journal-title":"J Exp Med"},{"key":"B80","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B81","doi-asserted-by":"publisher","first-page":"757","DOI":"10.3324\/haematol.2015.139253","article-title":"Frequent CTLA4-CD28 gene fusion in diverse types of T-cell lymphoma","volume":"101","author":"Yoo","year":"2016","journal-title":"Haematologica"},{"key":"B82","doi-asserted-by":"publisher","first-page":"5678","DOI":"10.1182\/blood-2011-09-380519","article-title":"Positive conversion of negative signaling of CTLA4 potentiates antitumor efficacy of adoptive T-cell therapy in murine tumor models","volume":"119","author":"Shin","year":"2012","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"5118","DOI":"10.1158\/0008-5472.CAN-16-0342","article-title":"CTLA4 promotes Tyk2-STAT3 dependent B cell oncogenecity","volume":"77","author":"Herrmann","year":"2017","journal-title":"Cancer Res"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4520","DOI":"10.1200\/JCO.2012.45.6004","article-title":"Activation of the STAT3 signaling pathway is associated with poor survival in diffuse large B-cell lymphoma treated with R-CHOP","volume":"31","author":"Huang","year":"2013","journal-title":"J Clin Oncol"},{"key":"B85","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"crossref","first-page":"abstr585","DOI":"10.1182\/blood.V126.23.585.585","article-title":"Preliminary safety and efficacy of the combination of brentuximab vedotin and ipilimumab in relapsed\/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer Research Group (E4412)","volume":"126","author":"Diefenbach","year":"2015","journal-title":"Blood"},{"key":"B87","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.it.2007.11.005","article-title":"HLA-G: from biology to clinical benefits","volume":"29","author":"Carosella","year":"2008","journal-title":"Trends Immunol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"4326495.1","DOI":"10.1155\/2016\/4326495","article-title":"Recent advances in our understanding of HLA-G biology: lessons from a wide spectrum of human diseases","volume":"2016","author":"Morandi","year":"2016","journal-title":"J Immunol Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.cytogfr.2014.04.004","article-title":"The emerging role of soluble HLA-G in the control of chemotaxis","volume":"25","author":"Morandi","year":"2014","journal-title":"Cytokine Growth Factor Rev"},{"key":"B90","doi-asserted-by":"publisher","first-page":"17957","DOI":"10.1073\/pnas.1221535110","article-title":"Exocytosis acts as a modulator of the ILT4-mediated inhibition of neutrophil functions","volume":"110","author":"Baudhuin","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B91","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1182\/blood-2005-12-019919","article-title":"Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells","volume":"108","author":"Fons","year":"2006","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1586\/ehm.09.72","article-title":"HLA-G expression in hematologic malignancies","volume":"3","author":"Yan","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1002\/gcc.22235","article-title":"Human leukocyte antigen-G polymorphisms influence the clinical outcome in diffuse large B-cell lymphoma","volume":"54","author":"Bielska","year":"2015","journal-title":"Genes Chromosomes Cancer"},{"key":"B94","doi-asserted-by":"publisher","first-page":"888","DOI":"10.3324\/haematol.2013.095281","article-title":"HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism","volume":"99","author":"Rizzo","year":"2014","journal-title":"Haematologica"},{"key":"B95","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1146\/annurev.cellbio.24.110707.175347","article-title":"Regulation of MHC class I assembly and peptide binding","volume":"24","author":"Peaper","year":"2008","journal-title":"Annu Rev Cell Dev Biol"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.5966\/sctm.2015-0049","article-title":"Targeted disruption of the beta2-microglobulin gene minimizes the immunogenicity of human embryonic stem cells","volume":"4","author":"Wang","year":"2015","journal-title":"Stem Cells Transl Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.ccr.2011.11.006","article-title":"Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma","volume":"20","author":"Challa-Malladi","year":"2011","journal-title":"Cancer Cell"},{"key":"B98","doi-asserted-by":"publisher","first-page":"70.1","DOI":"10.1186\/s13045-017-0438-7","article-title":"Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38\/07 prospective clinical trial cohort","volume":"10","author":"Juskevicius","year":"2017","journal-title":"J Hematol Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"Karre","year":"1986","journal-title":"Nature"},{"key":"B100","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ng.2873","article-title":"Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas","volume":"46","author":"Palomero","year":"2014","journal-title":"Nat Genet"},{"key":"B101","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"B102","doi-asserted-by":"publisher","first-page":"83294","DOI":"10.18632\/oncotarget.13065","article-title":"Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors","volume":"7","author":"Cao","year":"2016","journal-title":"Oncotarget"},{"key":"B103","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1002\/ijc.10824","article-title":"Beta2-microglobulin aberrations in diffuse large B-cell lymphoma of the testis and the central nervous system","volume":"103","author":"Jordanova","year":"2003","journal-title":"Int J Cancer"},{"key":"B104","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1111\/bjh.14633","article-title":"Mutational landscape of B-cell post-transplant lymphoproliferative disorders","volume":"178","author":"Menter","year":"2017","journal-title":"Br J Haematol"},{"key":"B105","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.4049\/jimmunol.152.4.1762","article-title":"Characterization of the human CD27 ligand, a novel member of the TNF gene family","volume":"152","author":"Hintzen","year":"1994","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.4049\/jimmunol.159.6.2652","article-title":"CD154\/CD40 and CD70\/CD27 interactions have different and sequential functions in T cell-dependent B cell responses: enhancement of plasma cell differentiation by CD27 signaling","volume":"159","author":"Jacquot","year":"1997","journal-title":"J Immunol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.4049\/jimmunol.180.6.3739","article-title":"CD27 defines phenotypically and functionally different human NK cell subsets","volume":"180","author":"Vossen","year":"2008","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1046\/j.1365-2141.1999.01573.x","article-title":"Aberrant expression and reverse signalling of CD70 on malignant B cells","volume":"106","author":"Lens","year":"1999","journal-title":"Br J Haematol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.bjc.6603222","article-title":"CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding","volume":"95","author":"Adam","year":"2006","journal-title":"Br J Cancer"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1182\/blood-2005-08-3376","article-title":"Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma","volume":"107","author":"Yang","year":"2006","journal-title":"Blood"},{"key":"B111","doi-asserted-by":"publisher","first-page":"5428","DOI":"10.1158\/0008-5472.CAN-04-4395","article-title":"Glioblastomas induce T-lymphocyte death by two distinct pathways involving gangliosides and CD70","volume":"65","author":"Chahlavi","year":"2005","journal-title":"Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1038\/leu.2014.84","article-title":"TGF-beta upregulates CD70 expression and induces exhaustion of effector memory T cells in B-cell non-Hodgkin\u2019s lymphoma","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"},{"key":"B113","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/sj.bjc.6605816","article-title":"Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75","volume":"103","author":"Ryan","year":"2010","journal-title":"Br J Cancer"},{"key":"B114","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1586\/1744666X.2014.865520","article-title":"The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy","volume":"10","author":"Ghiringhelli","year":"2014","journal-title":"Expert Rev Clin Immunol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.semcancer.2009.07.007","article-title":"How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt\u2019s lymphoma?","volume":"19","author":"Allday","year":"2009","journal-title":"Semin Cancer Biol"},{"key":"B116","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1053\/j.seminoncol.2014.12.030","article-title":"Epstein-Barr virus-associated lymphomas","volume":"42","author":"Grywalska","year":"2015","journal-title":"Semin Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.1182\/blood-2010-04-281873","article-title":"Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytes","volume":"116","author":"Barker","year":"2010","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1097\/00007890-200203270-00030","article-title":"Sustained remission of an extensive monoclonal, Epstein-Barr virus-associated diffuse large B cell lymphoma in a kidney-pancreas transplant recipient","volume":"73","author":"Manz","year":"2002","journal-title":"Transplantation"},{"key":"B119","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3324\/haematol.2016.141978","article-title":"Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients","volume":"101","author":"Laurent","year":"2016","journal-title":"Haematologica"},{"key":"B120","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-pathol-012513-104656","article-title":"Gammaherpesviruses and lymphoproliferative disorders","volume":"9","author":"Cesarman","year":"2014","journal-title":"Annu Rev Pathol"},{"key":"B121","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/path.4459","article-title":"The Epstein-Barr virus and the pathogenesis of lymphoma","volume":"235","author":"Vockerodt","year":"2015","journal-title":"J Pathol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"3786","DOI":"10.1182\/blood-2006-05-024109","article-title":"Hodgkin lymphoma and immunodeficiency in persons with HIV\/AIDS","volume":"108","author":"Biggar","year":"2006","journal-title":"Blood"},{"key":"B123","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1053\/j.seminoncol.2014.12.026","article-title":"Epstein-Barr virus- and Kaposi sarcoma-associated herpesvirus-related malignancies in the setting of human immunodeficiency virus infection","volume":"42","author":"Pinzone","year":"2015","journal-title":"Semin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1038\/363552a0","article-title":"A role for the ubiquitin-dependent proteolytic pathway in MHC class I-restricted antigen presentation","volume":"363","author":"Michalek","year":"1993","journal-title":"Nature"},{"key":"B125","doi-asserted-by":"publisher","first-page":"e1004304.1","DOI":"10.1371\/journal.ppat.1004304","article-title":"EBNA3C augments Pim-1 mediated phosphorylation and degradation of p21 to promote B-cell proliferation","volume":"10","author":"Banerjee","year":"2014","journal-title":"PLoS Pathog"},{"key":"B126","doi-asserted-by":"publisher","first-page":"5489","DOI":"10.1073\/pnas.0801053105","article-title":"EBV-encoded EBNA-6 binds and targets MRS18-2 to the nucleus, resulting in the disruption of pRb-E2F1 complexes","volume":"105","author":"Kashuba","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B127","doi-asserted-by":"publisher","first-page":"352","DOI":"10.3390\/v9110352","article-title":"Therapeutic strategies against Epstein-Barr virus-associated cancers using proteasome inhibitors","volume":"9","author":"Hui","year":"2017","journal-title":"Viruses"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1097\/01.pas.0000173023.02724.1f","article-title":"Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein-Barr virus-associated extramedullary plasmacytic neoplasm","volume":"29","author":"Dong","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"B129","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.leukres.2017.09.020","article-title":"Bortezomib in plasmablastic lymphoma: a glimpse of hope for a hard-to-treat disease","volume":"62","author":"Guerrero-Garcia","year":"2017","journal-title":"Leuk Res"},{"key":"B130","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ejca.2015.11.016","article-title":"Immune-related adverse events with immune checkpoint blockade: a comprehensive review","volume":"54","author":"Michot","year":"2016","journal-title":"Eur J Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1200\/JCO.2012.48.3685","article-title":"Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial","volume":"31","author":"Armand","year":"2013","journal-title":"J Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","first-page":"30","DOI":"10.3324\/haematol.2016.150656","article-title":"The emerging role of immune checkpoint inhibition in malignant lymphoma","volume":"102","author":"Hude","year":"2017","journal-title":"Haematologica"},{"key":"B133","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1056\/NEJMc1113863","article-title":"More on hemophilia A induced by ipilimumab","volume":"366","author":"Lozier","year":"2012","journal-title":"N Engl J Med"},{"key":"B134","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1056\/NEJMc1110923","article-title":"Hemophilia A induced by ipilimumab","volume":"365","author":"Delyon","year":"2011","journal-title":"N Engl J Med"},{"key":"B135","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s12254-010-0215-6","article-title":"Consideration of exposure to pharmacological agents helps to avoid diagnostic pitfalls in bone marrow histopathology","volume":"3","author":"Hoeller","year":"2010","journal-title":"memo"},{"key":"B136","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1172\/JCI85796","article-title":"Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality","volume":"126","author":"Saha","year":"2016","journal-title":"J Clin Invest"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00054\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T12:55:17Z","timestamp":1693572917000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2018.00054\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,7]]},"references-count":136,"alternative-id":["10.3389\/fonc.2018.00054"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2018.00054","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,7]]},"article-number":"54"}}